Natalia Neparidze, MD
Research & Publications
Biography
News
Research Summary
Developmental therapeutics, designing clinical trials in multiple myeloma, with specific interests in advanced imaging, tumor heterogeneity and tumor resistance in myeloma, strategies for advancing maintenance therapy, and eradication of minimal residual disease in multiple myeloma.
Extensive Research Description
My ongoing research direction includes incorporation and systematic use of advanced imaging with whole
body MRI in myeloma response assessment, and targeted biopsies of myeloma lesions to study tumor
heterogeneity, evaluate and compare genomic and transcriptome profile of focal lesions. As a result of my
collaboration with Yale Musculoskeletal Radiology, I developed and completed clinical trial (IIT) titled “Global
Response Assessment by Advanced Imaging and Lesion Biopsies During Induction Therapy of Multiple
Myeloma“ during 2018-2021. As part of a correlative project, we developed imaging scoring system evaluating
myeloma lesions by whole-body MRI and studying spatial heterogeneity of myeloma lesions.
Neparidze, N. Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: Influence
on treatment decisions. J Blood Disord Transfus. 2017 DOI: 10.4172/2155-9864-C1-022
I led the large-scale outcomes study utilizing Flatiron Myeloma cohort to examine the overall survival and
outcomes of patients with myeloma harboring chromosome 1 cytogenetic abnormalities (C1As). We
demonstrated that in this large cohort of patients with myeloma (N=3578) median OS was lower for patients
with C1As (46.6 vs 70.1 months). C1As were independently associated with worse OS, as were older age,
higher R-ISS stage, high-risk cytogenetic abnormalities, and immunoglobulin A isotype. C1As were associated
with inferior OS, independent of other high-risk cytogenetics, and despite greater use of novel therapies. We
concluded that clinical trials testing newer therapies for high-risk MM should incorporate patients with C1As.
Giri, S, and Neparidze, N et al. Chromosome 1 abnormalities and survival of patients with multiple myeloma in
the era of novel agents. Blood Adv 2020 May 26;4(10):2245-2253. doi: 10.1182/bloodadvances.2019001425.
My collaboration with Flatiron has led to another important outcomes study published in Leukemia examining
the impact of early COVID-19 pandemic in which we demonstrated that reasonable care continued for patients
with myeloma in the US despite challenges posed by the pandemic.
Neparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF.Changes in
multiple myeloma treatment patterns during the early COVID-19 pandemic period.Leukemia. 2022 Jun 27;. doi:
10.1038/s41375-022-01633-x. [Epub ahead of print] PubMed PMID: 35761025.
Recent / ongoing research:
Agency: Yale Cancer Center, Janssen
Title: IIS. Prospective, Observational Study of Real-world Efficacy and Quality of Life Outcomes with
Daratumumab Regimens in Relapsed MM
PI: Natalia Neparidze, MD
Aim: This investigator-initiated, multicenter, clinical research study is aimed to evaluate a real-world efficacy
and patient-reported health-related quality of life outcomes in an observational prospective manner.
Agency: Flatiron and Yale COPPER / School of Public Health
ID YCC/COPPER
PI: Natalia Neparidze, MD
Title: Chromosome 1 Abnormalities and Clinical Outcomes in Multiple Myeloma in the Era of Novel Agents
This study evaluated clinical outcomes in patients with multiple myeloma and Chromosome 1 aberrations
utilizing Flatiron multiple myeloma cohort of over 8000 patients.
Agency: DeLuca Foundation
PI: Natalia Neparidze, MD
Title: Evaluation of Clonal Heterogeneity and Therapeutic Targets in Multiple Myeloma.
Aim: This study evaluated myeloma clonal spatial heterogeneity by comparing genome abnormalities between
bone marrow and myeloma lesions to identify actionable targets for treatment.
Agency: GlaxoSmithKline.
PI: Natalia Neparidze, MD
Title of IIS: Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in
Multiple Myeloma.
This study evaluates the novel immunotherapy combination with antibody-drug conjugate Belantamab
Mafodotin plus a checkpoint inhibitor elotuzumab in patients with relapsed/refractory myeloma.
“Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma” is my earliest significant published work. I was involved as this translational research study was designed and launched at Yale University. I was subsequently involved in screening, enrolling and treating the patients on this phase I/II trial. Natural killer T cells can help mediate immune surveillance against tumors. They play an important role as orchestrators of immune system in multiple myeloma. Clinical myeloma is preceded by an asymptomatic precursor phase.
We treated patients with asymptomatic myeloma with combination of lipid α-galactosylceramide-loaded dendritic
cells and low-dose lenalidomide. The treatment was well tolerated and resulted in clinical responses. Clinical
responses correlated with treatment-induced antitumor T-cell immunity. Broad changes in the repertoire of NKT
cells, activation of monocyte/macrophage system and eosinophils was observed. These data demonstrated
synergistic activation of several innate immune cells by this combination and the capacity to mediate tumor
regression. The study provided an important, first-in-human experience with targeting lipid reactive T cells in
combination with lenalidomide in myeloma. This was an important proof-of concept study demonstrating that
combination therapies targeting NKT cells may be of benefit toward prevention of cancer in humans. Additionally,
the study greatly enhanced our understanding of subsets of lipid-reactive NKT cells, which paved the wave for
further seminal work on lipid antigens in the origins of myeloma by our group.
Neparidze, N and Dhodapkar, MV. Understanding the role of Natural Killer T (NKT) cells in
hematologic malignancies: progress and challenges. Chapter. Natural Killer T Cells. Cancer Drug
Discovery and Development 2012, pp 153-167
J. Richter, N. Neparidze, L. Zhang, S. Nair, T. Monesmith, R. Sundaram, F. Miesowicz, K. M.
Dhodapkar, and M. V. Dhodapkar. Clinical regressions and broad immune activation following
combination therapy targeting human NKT cells in myeloma. Plenary Paper. Blood -2013 121:423-430
At the VA CT Cancer Center I evaluated the efficiency, clinical outcomes and patient /provider satisfaction of
newly implemented electronic hematology consults at VACT. We concluded that in an integrated health care
system with a comprehensive EMR, e-consults offer a timely and patient-centered option for providing
hematology specialist input for select patients. Further studies are necessary to determine the role this method
of delivering hematologic care and its effect on our health care system, how virtual care workload should be
compensated, its impact on the workload of hematologists, and the quality of care delivered.
Cecchini M, Rose MG, Wong EY, and Neparidze N. The implementation of electronic hematology consults
at a VA Hospital. Blood. 2016 Jan 2509-672113
While serving at VA CT Cancer Center, I developed a protocol under the auspices of VACS – Veterans Aging
Cohort Study, with the aim to evaluate biology and clinical outcomes of multiple myeloma in association with HIV
infection. Analysis of the data from the VACS cohorts of HIV-infected and HIV-uninfected veterans with multiple
myeloma is ongoing to compare clinical, morphologic and genomic features of HIV-associated myeloma. This
study is expected to provide significant insights into disease biology, outcomes and treatment of patients with
myeloma and HIV infection.
Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma.
Smith Giri, Ellice Y. Wong, Michal Rose, Roxanne Wadia, Lesley S. Park, Amy
Justice and Natalia Neparidze Blood 2018 132:3162; doi: https://doi.org/10.1182/blood-...
Coauthors
Research Interests
Amyloidosis; Hematology; Leukemia, Plasma Cell; Waldenstrom Macroglobulinemia; Multiple Myeloma; Myeloma Proteins; Paraproteinemias; Neoplasms, Plasma Cell; Smoldering Multiple Myeloma
Selected Publications
- Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United StatesPatell R, Midha S, Kimani S, Martin R, Neparidze N, Jaglal M, Freed J, Key NS. Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States Thrombosis And Haemostasis 2020, 120: 1725-1732. PMID: 32828072, PMCID: PMC7869034, DOI: 10.1055/s-0040-1715837.
- Association of iron infusion reactions with ABO blood typeButt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Association of iron infusion reactions with ABO blood type European Journal Of Haematology 2022, 109: 519-525. PMID: 35871468, DOI: 10.1111/ejh.13838.
- Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic periodNeparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF. Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period Leukemia 2022, 36: 2136-2139. PMID: 35761025, PMCID: PMC9243711, DOI: 10.1038/s41375-022-01633-x.
- Refractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: A clinical case reportCrawford LR, Neparidze N. Refractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: A clinical case report Clinical Case Reports 2022, 10: e05583. PMID: 35340637, PMCID: PMC8933632, DOI: 10.1002/ccr3.5583.
- Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with RuxolitinibStempel J, Wang R, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Ma X, Podoltsev N. Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib Blood 2022, 140: 11004-11006. DOI: 10.1182/blood-2022-165156.
- Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple MyelomaBrowning S, Liu Y, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Syam R, Gorshein E, DiAdamo A, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Wei W, Haims A, Neparidze N. Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma Blood 2022, 140: 7308-7310. DOI: 10.1182/blood-2022-166325.
- Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction TherapyLiu Y, Browning S, VanOudenhove J, Biancon G, Bar N, Parker T, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Haims A, Wei W, Neparidze N. Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy Blood 2022, 140: 7086-7087. DOI: 10.1182/blood-2022-168109.
- Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene VicleucelMirza A, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, VanOudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel Blood 2022, 140: 10410-10412. DOI: 10.1182/blood-2022-168374.
- Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: A population-based analysisDi M, Cui C, Kothari S, Zeidan AM, Podoltsev NA, Neparidze N, Shallis RM, Wang R, Ma X, Huntington SF. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: A population-based analysis Blood Advances 2022, 6: 3339-3342. PMID: 35240689, PMCID: PMC9198937, DOI: 10.1182/bloodadvances.2021006934.
- Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United StatesBewersdorf JP, Prozora S, Podoltsev NA, Shallis RM, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.
- Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United StatesParikh RB, Takvorian SU, Vader D, Wileyto E, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R, Hubbard RA, Investigators T. Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States Journal Of The National Cancer Institute 2021, 114: 571-578. PMID: 34893865, PMCID: PMC9002283, DOI: 10.1093/jnci/djab225.
- Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale ExperienceLiu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience Blood 2021, 138: 1635-1635. DOI: 10.1182/blood-2021-146619.
- Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer CenterDosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center Blood 2021, 138: 4756-4756. DOI: 10.1182/blood-2021-147466.
- Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agent Monotherapy in the Frontline SettingBewersdorf J, Wei W, Jaiani A, Patel P, Mehta R, Neparidze N, Shallis R, Podoltsev N, Brunner A, Zeidan A. Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agent Monotherapy in the Frontline Setting Blood 2021, 138: 3701-3701. DOI: 10.1182/blood-2021-146331.
- Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based AnalysisDi M, Cui C, Kothari S, Zeidan A, Podoltsev N, Neparidze N, Shallis R, Wang R, Ma X, Huntington S. Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis Blood 2021, 138: 182-182. DOI: 10.1182/blood-2021-146417.
- Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic PeriodNeparidze N, Wang R, Zeidan A, Podoltsev N, Shallis R, Ma X, Davidoff A, Huntington S. Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period Blood 2021, 138: 4092-4092. PMCID: PMC8701553, DOI: 10.1182/blood-2021-148998.
- Contemporary "Real World" Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United StatesShallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Di M, Ma X, Podoltsev N. Contemporary "Real World" Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States Blood 2021, 138: 282-282. DOI: 10.1182/blood-2021-151066.
- Iron Infusion Reactions: Risk Factors and Real-World ExperienceButt A, Muradashvili T, Soliman S, Goshua G, Burns A, Bar N, Martin K, Borgman G, Bona R, Lee A, Neparidze N. Iron Infusion Reactions: Risk Factors and Real-World Experience Blood 2021, 138: 4154-4154. DOI: 10.1182/blood-2021-151048.
- Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived DatabaseCalip G, Ascha M, Wang X, Pierre A, Maignan K, Wadé N, Leng S, Seymour E, Chiu B, Sweiss K, Patel P, Neparidze N. Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database Blood 2021, 138: 4121-4121. DOI: 10.1182/blood-2021-152774.
- Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United StatesGoyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States Blood 2021, 138: 1930-1930. PMCID: PMC8701834, DOI: 10.1182/blood-2021-153625.
- Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United StatesNeparidze N, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States Blood 2021, 138: 1973-1973. PMCID: PMC8701527, DOI: 10.1182/blood-2021-153787.
- Impact of the COVID-19 pandemic on treatment patterns for US patients with metastatic solid cancer.Parikh RB, Takvorian SU, Vader D, Wileyto EP, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R, Hubbard RA. Impact of the COVID-19 pandemic on treatment patterns for US patients with metastatic solid cancer. MedRxiv : The Preprint Server For Health Sciences 2021 PMID: 34611665, PMCID: PMC8491856, DOI: 10.1101/2021.09.22.21263964.
- Challenges in the evaluation and management of toxicities arising from immune checkpoint inhibitor therapy for patients with myeloid malignanciesShallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the evaluation and management of toxicities arising from immune checkpoint inhibitor therapy for patients with myeloid malignancies Clinical Lymphoma Myeloma & Leukemia 2021, 21: e483-e487. PMID: 33551344, DOI: 10.1016/j.clml.2021.01.003.
- Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal Of Clinical Oncology 2021, 39: 1119-1128. PMID: 33411586, DOI: 10.1200/jco.20.01849.
- A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)Parker T, Rosenthal A, Sanchorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Hagen P, Sarosiek S, Scott E, Hoering A, Durie B, Usmani S, Orlowski R. A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808) Blood 2020, 136: 20-21. DOI: 10.1182/blood-2020-143180.
- Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple MyelomaBrowning S, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Lee A, Prebet T, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Lischuk A, Wei W, Haims A, Neparidze N. Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma Blood 2020, 136: 20-22. DOI: 10.1182/blood-2020-136478.
- Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic LeukemiaBewersdorf J, Prozora S, Wang R, Podoltsev N, Shallis R, Huntington S, Neparidze N, Ma X, Gore S, Zeidan A, Davidoff A. Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-136983.
- Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and OutcomesDavidoff A, Long J, Neparidze N, Bewersdorf J, Shallis R, Podoltsev N, Wang R, Gore S, Zeidan A, Huntington S. Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes Blood 2020, 136: 2-3. DOI: 10.1182/blood-2020-140728.
- Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional studyGoshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.
- Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancerBar N, Costa F, Das R, Duffy A, Samur M, McCachren S, Gettinger S, Neparidze N, Parker TL, Bailur JK, Pendleton K, Bajpai R, Zhang L, Xu ML, Anderson T, Giuliani N, Nooka A, Cho HJ, Raval A, Shanmugam M, Dhodapkar KM, Dhodapkar M. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer JCI Insight 2020, 5 PMID: 32427579, PMCID: PMC7406262, DOI: 10.1172/jci.insight.129353.
- Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agentsGiri S, Huntington SF, Wang R, Zeidan AM, Podoltsev N, Gore SD, Ma X, Gross CP, Davidoff AJ, Neparidze N. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents Blood Advances 2020, 4: 2245-2253. PMID: 32442299, PMCID: PMC7252537, DOI: 10.1182/bloodadvances.2019001425.
- Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United StatesZeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.
- Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status.Davidoff A, Long J, Bewersdorf J, Shallis R, Zeidan A, Podoltsev N, Wang R, Gore S, Giri S, Neparidze N, Huntington S. Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status. Journal Of Clinical Oncology 2020, 38: e19057-e19057. DOI: 10.1200/jco.2020.38.15_suppl.e19057.
- Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United StatesZeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States Blood Advances 2020, 4: 1615-1623. PMID: 32311013, PMCID: PMC7189301, DOI: 10.1182/bloodadvances.2020001728.
- Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center ExperienceBewersdorf J, Shallis R, Gowda L, Hager K, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience Blood 2019, 134: 5173-5173. DOI: 10.1182/blood-2019-127162.
- Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?Bewersdorf J, Shallis R, Diadamo A, Gowda L, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought? Blood 2019, 134: 5174-5174. DOI: 10.1182/blood-2019-127277.
- Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center ExperienceShallis R, Bewersdorf J, Gowda L, Podoltsev N, Prebet T, Gore S, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Zeidan A. Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience Blood 2019, 134: 1330-1330. DOI: 10.1182/blood-2019-127422.
- Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer CenterBrowning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center Blood 2019, 134: 5569-5569. DOI: 10.1182/blood-2019-130134.
- Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based StudyZeidan A, Podoltsev N, Wang X, Bewersdorf J, Shallis R, Huntington S, Neparidze N, Giri S, Gore S, Ma X, Davidoff A, Wang R. Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study Blood 2019, 134: 116-116. DOI: 10.1182/blood-2019-126643.
- Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United StatesZeidan A, Wang R, Wang X, Shallis R, Podoltsev N, Bewersdorf J, Huntington S, Neparidze N, Giri S, Gore S, Davidoff A, Ma X. Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States Blood 2019, 134: 646-646. DOI: 10.1182/blood-2019-127398.
- Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaGonsalves W, Devarakonda S, Baz R, Neparidze N, Adjei A, Kunos C, Kumar S. Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Blood 2019, 134: 3160-3160. DOI: 10.1182/blood-2019-123399.
- Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United StatesGiri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore SD, Neparidze N, Ma X, Gross CP, Davidoff AJ, Huntington SF. Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United States Cancer 2019, 125: 4084-4095. PMID: 31381151, DOI: 10.1002/cncr.32428.
- Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathyBailur JK, McCachren SS, Doxie DB, Shrestha M, Pendleton K, Nooka AK, Neparidze N, Parker TL, Bar N, Kaufman JL, Hofmeister CC, Boise LH, Lonial S, Kemp ML, Dhodapkar KM, Dhodapkar MV. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy JCI Insight 2019, 5 PMID: 31013254, PMCID: PMC6629164, DOI: 10.1172/jci.insight.127807.
- Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.
- A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studiesSong Y, Rongvaux A, Taylor A, Jiang T, Tebaldi T, Balasubramanian K, Bagale A, Terzi YK, Gbyli R, Wang X, Fu X, Gao Y, Zhao J, Podoltsev N, Xu M, Neparidze N, Wong E, Torres R, Bruscia EM, Kluger Y, Manz MG, Flavell RA, Halene S. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies Nature Communications 2019, 10: 366. PMID: 30664659, PMCID: PMC6341122, DOI: 10.1038/s41467-018-08166-x.
- Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous ThromboembolismShevell L, Lee E, Dhodapkar R, Dykas D, Popa A, Ma D, Bar N, Baluha A, Burns A, Ochoa Chaar C, Dupont A, Gu S, Halene S, Luciano R, Marien R, Neparidze N, Parker T, Yao X, Camire R, Ebberink E, Garcia de Frutos P, Gnanasambandan K, Sayeski P, Huntington J, Lentz S, Mertens K, Parish C, Rezaie R, Connors J, Leavitt A, Bale A, Lee A. Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism Blood 2018, 132: 2506-2506. DOI: 10.1182/blood-2018-99-115529.
- Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple MyelomaCho H, Costa L, Davies F, Neparidze N, Vij R, Feng Y, Teterina A, Wassner Fritsch E, Wenger M, Kaufman J. Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma Blood 2018, 132: 597-597. DOI: 10.1182/blood-2018-99-114960.
- Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple MyelomaGiri S, Wong E, Rose M, Wadia R, Park L, Justice A, Neparidze N. Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma Blood 2018, 132: 3162-3162. DOI: 10.1182/blood-2018-99-115633.
- Venous Thromboembolism (VTE) Education Preferences Amongst Physicians and Patients: A Qualitative Needs AssessmentJuthani P, Ahmed D, Ahmed O, Bona R, Neparidze N, Lee A. Venous Thromboembolism (VTE) Education Preferences Amongst Physicians and Patients: A Qualitative Needs Assessment Blood 2018, 132: 5810-5810. DOI: 10.1182/blood-2018-99-119418.
- Antigen-mediated regulation in monoclonal gammopathies and myelomaNair S, Sng J, Boddupalli CS, Seckinger A, Chesi M, Fulciniti M, Zhang L, Rauniyar N, Lopez M, Neparidze N, Parker T, Munshi NC, Sexton R, Barlogie B, Orlowski R, Bergsagel L, Hose D, Flavell RA, Mistry PK, Meffre E, Dhodapkar MV. Antigen-mediated regulation in monoclonal gammopathies and myeloma JCI Insight 2018, 3: e98259. PMID: 29669929, PMCID: PMC5931125, DOI: 10.1172/jci.insight.98259.
- Hyperbilirubinemia following lenalidomide administrationAzmy V, Neparidze N. Hyperbilirubinemia following lenalidomide administration Clinical Case Reports 2018, 6: 875-877. PMID: 29744077, PMCID: PMC5930194, DOI: 10.1002/ccr3.1471.
- Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapyBailur J, Mehta S, Zhang L, Neparidze N, Parker T, Bar N, Anderson T, Xu ML, Dhodapkar KM, Dhodapkar MV. Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy Blood Advances 2017, 1: 2343-2347. PMID: 29296884, PMCID: PMC5729633, DOI: 10.1182/bloodadvances.2017012732.
- Whole-exome sequencing in evaluation of patients with venous thromboembolismLee EJ, Dykas DJ, Leavitt AD, Camire RM, Ebberink E, García de Frutos P, Gnanasambandan K, Gu SX, Huntington JA, Lentz SR, Mertens K, Parish CR, Rezaie AR, Sayeski PP, Cromwell C, Bar N, Halene S, Neparidze N, Parker TL, Burns AJ, Dumont A, Yao X, Chaar CIO, Connors JM, Bale AE, Lee AI. Whole-exome sequencing in evaluation of patients with venous thromboembolism Blood Advances 2017, 1: 1224-1237. PMID: 29296762, PMCID: PMC5728544, DOI: 10.1182/bloodadvances.2017005249.
- Asymmetric Deep Stromal Keratopathy in a Patient With Multiple MyelomaTainsh LT, Coady PA, Sinard JH, Neparidze N, Meskin SW, Adelman RA, Chow J. Asymmetric Deep Stromal Keratopathy in a Patient With Multiple Myeloma Cornea 2017, 36: 372-374. PMID: 28079685, DOI: 10.1097/ico.0000000000001139.
- The implementation of electronic hematology consults at a VA hospital.Cecchini M, Rose MG, Wong EY, Neparidze N. The implementation of electronic hematology consults at a VA hospital. Blood 2016, 127: 1610-1. PMID: 26809506, PMCID: PMC4807425, DOI: 10.1182/blood-2015-09-672113.
- Efficient Engraftment and Disease Replication of Myelodysplastic Syndromes Using a Novel Humanized Mice ModelSong Y, Taylor A, Rongvaux A, Jiang T, Podoltsev N, Xu M, Neparidze N, Torres R, Barbarotta L, Balasubramanian K, Finberg K, Kluger Y, Flavell R, Halene S. Efficient Engraftment and Disease Replication of Myelodysplastic Syndromes Using a Novel Humanized Mice Model Blood 2015, 126: 4100-4100. DOI: 10.1182/blood.v126.23.4100.4100.
- 26 HUMANIZED MICE AFFORD EFFICIENT ENGRAFTMENT AND DISEASE REPLICATION OF MYELODYSPLASTIC SYNDROMESSong Y, Rongvaux A, Taylor A, Podoltsev N, Xu M, Neparidze N, Torres R, Barbarotta L, Balasubramanian K, Finberg K, Flavell R, Halene S. 26 HUMANIZED MICE AFFORD EFFICIENT ENGRAFTMENT AND DISEASE REPLICATION OF MYELODYSPLASTIC SYNDROMES Leukemia Research 2015, 39: s11-s12. DOI: 10.1016/s0145-2126(15)30027-8.
- Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient SatisfactionNeparidze N, Cecchini M, Wong E, Rose M. Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient Satisfaction Blood 2014, 124: 4857-4857. DOI: 10.1182/blood.v124.21.4857.4857.
- Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments.Neparidze N, Lacy J. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. Clinical Advances In Hematology And Oncology 2014, 12: 358-71. PMID: 25003566.
- Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myelomaRichter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R, Miesowicz F, Dhodapkar KM, Dhodapkar MV. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma Blood 2012, 121: 423-430. PMID: 23100308, PMCID: PMC3548165, DOI: 10.1182/blood-2012-06-435503.
- Understanding the role of Natural Killer T (NKT) cells in hematologic malignancies: progress and challenges.Neparidze N and Dhodapkar, MV. Chapter. Natural Killer T Cells. Cancer Drug Discovery and Development 2012, pp 153-167
- Understanding the Role of Natural Killer T Cells in Hematologic Malignancies: Progress and ChallengesNeparidze N, Dhodapkar M. Understanding the Role of Natural Killer T Cells in Hematologic Malignancies: Progress and Challenges 2011, 153-167. DOI: 10.1007/978-1-4614-0613-6_9.
- Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.Neparidze N, Dhodapkar MV. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy. Clinical Advances In Hematology And Oncology 2009, 7: 677-81, 687-90. PMID: 20040909, PMCID: PMC3612541.
- Harnessing CD1d‐Restricted T Cells toward Antitumor Immunity in HumansNeparidze N, Dhodapkar MV. Harnessing CD1d‐Restricted T Cells toward Antitumor Immunity in Humans Annals Of The New York Academy Of Sciences 2009, 1174: 61-67. PMID: 19769737, PMCID: PMC2782771, DOI: 10.1111/j.1749-6632.2009.04931.x.
- NKT cells in p53 deficiencyDhodapkar MV, Neparidze N. NKT cells in p53 deficiency Blood 2009, 113: 6268-6269. PMID: 19541831, DOI: 10.1182/blood-2009-03-211318.
- Hetastarch haemophiliaNEPARIDZE N, KRIZ N, ORNSTEIN DL. Hetastarch haemophilia Haemophilia 2009, 15: 976-979. PMID: 19473419, DOI: 10.1111/j.1365-2516.2009.02023.x.
- Human Keratinocytes Express Functional CD14 and Toll-Like Receptor 4Song PI, Neparidze N, Armstrong C, Ansel J, Park Y, Abraham T, Harten B, Zivony A. Human Keratinocytes Express Functional CD14 and Toll-Like Receptor 4 Journal Of Investigative Dermatology 2002, 119: 424-432. PMID: 12190866, DOI: 10.1046/j.1523-1747.2002.01847.x.